According to the 27 July announcement, Prendergast next week in Florida will be presenting “expanded details of in-vitro, in-vivo and human clinical trial data” on R327’s relevance to the treatment of wound infections in military personnel. “A non-confidential version of the Poster and Abstract materials will be available on the Company’s website, post-conference.”
The details in this Special Access announcement make it pretty clear what value R327 could hold for the health and functioning of the US military. It would not be a customer needing to wait for commercial regulatory approvals, and also would have ready access to trial ‘volunteers’ if required (and research funds?).
According to the 27 July announcement, Prendergast next week in...
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
50.0¢ |
Change
-0.010(1.96%) |
Mkt cap ! $115.8M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 55.0¢ | 50.0¢ | $168.7K | 317.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6252 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 13561 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RCE (ASX) Chart |